

## IN THE CLAIMS

Please substitute the following set of claims for those currently of record:

1. (Currently amended) A method for treating tumors in a mammal comprising:  
administering to the mammal spores of a toxin-defective, anaerobic bacterium  
selected from the group consisting of *Clostridium novyi* and *Clostridium sordellii*; and  
administering to the mammal a microtubule stabilizing anti-tumor agent; whereby  
the tumor regresses or its growth is slowed or arrested.
2. (Original) The method of claim 1 wherein the anaerobic bacterium is *Clostridium novyi*.
3. (Original) The method of claim 1 wherein the anaerobic bacterium is *Clostridium sordellii*.
4. (Original) The method of claim 1 wherein the spores are administered intravenously.
5. (Original) The method of claim 1 wherein the spores are administered intratumorally.
6. (Original) The method of claim 1 wherein all or part of a toxin gene of a wild type form of the anaerobic bacterium is deleted.
7. (Currently amended) The method of claim 1 wherein the microtubule stabilizing anti-tumor agent is a taxane.
8. (Currently amended) The method of claim 1 wherein the microtubule stabilizing anti-tumor agent is selected from the group consisting of 10-deacetyltaxol; 7-epi-10-deacetyltaxol; 7-xylosyl-10-deacetyltaxol; 7-epi-taxol; cephalomannine; baccatin III; baccatin V; 10-deacetylbaccatin III; 7-epi-10-deacetylbaccatin III; 2-debenzoyl-2-(p-trifluoromethylbenzoyl)taxol; and 20-acetoxy-4-deacetyl-5-epi-20, O-secotaxol.
9. (Currently amended) The method of claim 1 wherein the microtubule stabilizing anti-tumor agent is selected from the group consisting of arsenic trioxide, discodermolide, epothilone B, and (+)-14-normethyldiscodermolide.

10. (Currently amended) The method of claim 1 wherein the microtubule stabilizing anti-tumor agent is taxol.
11. (Currently amended) The method of claim 1 wherein the microtubule stabilizing anti-tumor agent is taxotere.
12. (Currently amended) The method of claim 1 wherein the microtubule stabilizing anti-tumor agent is cephalomannine.
13. (Original) The method of claim 1 further comprising:  
administering a nitric oxide synthetase (NOS) inhibitor to the mammal.
14. (Currently amended) The method of claim 1 wherein the spores and microtubule stabilizing anti-tumor agent are administered serially.
15. (Currently amended) The method of claim 13 wherein the spores, microtubule stabilizing anti-tumor agent and NOS inhibitor are administered serially.
16. (Currently amended) A kit for treating tumors, wherein components of the kit are in a divided or undivided container, said components comprising:  
spores of a toxin-defective, anaerobic bacterium selected from the group consisting of *Clostridium novyi* and *Clostridium sordellii*; and  
a microtubule stabilizing, anti-tumor agent.
17. (Original) The kit of claim 16 wherein all or part of a toxin gene of a wild type form of the anaerobic bacterium is deleted in the spores of the anaerobic bacterium.
18. (Original) The kit of claim 16 further comprising a nitric oxide synthetase inhibitor.
19. (Original) The kit of claim 16 wherein the anaerobic bacterium is *Clostridium novyi*.
20. (Original) The kit of claim 16 wherein the anaerobic bacterium is *Clostridium sordellii*.
21. (Currently amended) The kit of claim 16 wherein the microtubule stabilizing anti-tumor agent is taxol.
22. (Currently amended) The kit of claim 16 wherein the microtubule stabilizing anti-tumor agent is taxotere.
23. (Currently amended) The kit of claim 16 wherein the microtubule stabilizing anti-tumor agent is cephalomannine.

24. (Currently amended) The kit of claim 16 wherein the microtubule stabilizing anti-tumor agent is a taxane.

25. (Previously presented) The method of claim 1 wherein the toxicity of the toxin-defective, anaerobic bacterium is reduced by a factor of at least 2 compared to a corresponding wild-type bacterium.

26. (Previously presented) The method of claim 2 wherein the toxicity of the toxin-defective *Clostridium novyi* is reduced by a factor of at least 2 compared to a corresponding *Clostridium novyi*.

27. (Previously presented) The kit of claim 16 wherein the toxicity of the toxin-defective, anaerobic bacterium is reduced by a factor of at least 2 compared to a corresponding wild-type bacterium.

28. (Previously presented) The kit of claim 19 wherein the toxicity of the toxin-defective *Clostridium novyi* is reduced by a factor of at least 2 compared to a corresponding *Clostridium novyi*.